No cognitive benefit from BP, lipid lowering in HOPE-3

  • Neurology

  • curated by Susan London
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Older adults at intermediate cardiovascular risk do not have better cognition if treated long term with candesartan plus hydrochlorothiazide (Atacand HCT), rosuvastatin (Crestor), or their combination.

Why this matters

  • High prevalence and toll of cognitive impairment and dementia in the geriatric population.

Key results

  • Compared with placebo:
    • Candesartan-hydrochlorothiazide (HCTZ) reduced systolic blood pressure by 6.0 mm Hg.
    • Rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL.
  • With median 5.7-year follow-up, mean difference in change in Digit Symbol Substitution Test scores vs placebos:
    • −0.91 (95% CI, −2.25 to 0.42) for candesartan-HCTZ.
    • −0.54 (95% CI, −1.88 to 0.80) for rosuvastatin.
    • −1.43 (95% CI, −3.37 to 0.50) for combination.
  • No significant differences in modified Montreal Cognitive Assessment, TrailMaking Test Part B.

Expert comment

  • In an editorial, Christopher Chen, MD, and Craig S. Anderson, MD, PhD, write, "Big data analytics of diverse populations, differing treatment approaches, longer duration of follow-up, and statistical approaches to adjust for confounding might overcome the inherent limitations of randomized controlled trials. Even delaying the onset of dementia by a year could accomplish immense public health improvement."

Study design

  • Randomized controlled trial with 2 by 2 factorial design having 2361 adults aged ≥70 years without known cardiovascular disease or need for treatment, but with ≥1 additional cardiovascular risk factors (HOPE-3 trial).
  • Randomization: double-blind candesartan (16 mg)+HCTZ (12.5 mg) vs placebo, and rosuvastatin (10 mg) vs placebo.
  • Main outcome: cognitive function.
  • Funding: Canadian Institutes of Health Research; AstraZeneca.

Limitations

  • Missing outcome data for ~25% of participants.
  • Final assessment often done by telephone.
  • Possibility that follow-up not long enough.